The 13th Congress of the World Federation of Nuclear Medicine and Biology / The 62nd Annual Scientific Meeting of the Japanese Society of Nuclear Medicine / The 42nd Annual Meeting of the Japanese Society of Nuclear Medicine Technology

Luncheon Seminar 16
Amyloid biomarkers of dementia

Date
September 10, 2022(Sat.)
12:30~13:30
Place

Kyoto International Conference Center Room5(Room B-1)

Chairman
Dr. Hidehiko Okazawa
Professor, University of Fukui, Biomedical Imaging Research Center
Speaker 1

Blood-based biomarkers for dementia: Current status and future directions

Dr. Akinori Nakamura
Professor, Department of Biomarker Research, National Center for Geriatrics and Gerontology

Speaker 2

High resolution dedicated head PET scanner for molecular imaging of dementia

Dr. Kazunari Ishii
Chief Professor, Kindai University Faculty of Medicine, Department of Radiology

*This seminar will be conducted in English.

View a PDF file

Work in Progress

Date
September 9, 2022 (Fri.)
15:15~17:15
(Five companies, including Shimadzu, will present.)
Place

Kyoto International Conference Center 2F(Room 4)

Title

BresTome TOF-PET system and Advanced Healthcare of Shimadzu

Yoshiyuki Yamakawa
Research & Development Department, Medical Systems Division, Shimadzu Corporation

Our Response to Dementia

【Video】A precious anniversary
- Shimadzu's Response to Dementia -

Researchers’ Passion and Study of Blood-based Biomarkers - Useful for Early Detection of Alzheimer’s Disease

Researchers’ Passion and Study of Blood-based Biomarkers - Useful for Early Detection of Alzheimer’s Disease

Akinori Nakamura
Doctor of Medicine/Neurologist
Professor, Department of Biomarker Research, The National Center for Geriatrics and Gerontology

From Ultra-early Diagnostics to Prognosis Management of Dementia

  1. Ultra-early Diagnostics
  2. Diagnostics
  3. Treatment
  4. Prognosis
Amyloid-MS

Amyloid-MS

Predicting Amyloid-beta Deposition Levels in the Brain from a Blood Test

BresTome TOF-PET Scanner

BresTome TOF-PET Scanner

Visualizing Amyloid-beta Deposition in the Brain using PET Imaging

fNIRS

fNIRS

Evaluating Cognitive Function by Optical Brain Function Imaging

Related Information

Please contact us for any materials you are interested in.

Conference

For more details: https://www.shimadzu.eu/aaic-2020

Poster

MALDI-TOF IP-MS quantification of plasma amyloid peptides in Alzheimer’s disease

Sylvain Lehmann, CHU Montpellier, France

Poster

Identification of ADAMTS4 as an APP-cleaving enzyme at 669 site in APP669-711 production pathway

Taisuke Tomita, The University of Tokyo, Japan

Poster

Plasma Aβ biomarker associated with cognitive decline in preclinical Alzheimer’s disease

Yen Ying Lim, The Florey Institute of Neuroscience and Mental Health, Australia

Poster

Studies on the Pragmatic Performance and Validity of a Plasma Amyloid β Measurement System by Immunoprecipitation-Mass Spectrometry

Naoki Kaneko, Shimadzu Corporation, Japan

For more details: https://www.shimadzu.eu/aaic-2021

Poster

Semi-quantitative assay for Neurogranin peptides using IP-MALDI-MS

Naoki Kaneko, Shimadzu Corporation, Kyoto, Japan

Poster

Analytical Validation of Plasma Amyloid β Measuring System by Immunoprecipitation-Mass Spectrometry

Ritsuko Yoda, Shimadzu Corporation, Kyoto, Japan

Poster

The APP669-711/Aβ1-40 ratio as a plasma biomarker specific for the brain Aβ deposition in APP/PS1 mouse

Naoki Kaneko, Shimadzu Corporation, Kyoto, Japan

For more details: https://www.shimadzu.eu/msacl-eu-21

Corporate Workshop

Blood test for neurodegenerative diseases: Are we ready? - Implementation of high-performance plasma amyloid-beta quantification for Alzheimer's diagnostic on the Clinical Proteomics Platform of Montpellier Hospital (France)

Pr. Christophe Hirtz, PPC, IRMB, Hospital Saint Eloi, Montpellier, France (general presentation)
Jana Kindermans, PPC, IRMB, Hospital Saint Eloi, Montpellier, France (analytical validation, clinical validation)

Cohort research

Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias

PhD, MD, Daniel Alcolea, Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau, Barcelona (Spain)

Journal of Neurology, Neurosurgery & Psychiatry